Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
NCT ID: NCT00446329
Last Updated: 2014-10-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE4
15 participants
INTERVENTIONAL
2006-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The 2nd phase of the study designed to evaluate the long term effects of cinacalcet on BMD (bone mineral density)and the levels of PTH, calcium, phosphorus as well as its ability to control secondary hyperparathyroidism without simultaneous administration of other vitamin D compounds.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cinacalcet in Management of Secondary Hyperparathyroidism in Haemodialysis Patients
NCT02338934
Study for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients
NCT00042432
Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis
NCT00094484
Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level
NCT01101113
Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis
NCT02138838
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
cinacalcet
Initiation dose of cinacalcet 30 mg/day. Titration every 2-3 weeks with a maximum dose of 180 mg/day.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* On hemodialysis for at least 3 months (thrice weekly)
* iPTH \>300pg/ml or histological evidence of secondary hyperparathyroidism
* Calcium \> 8.1 mg/dl
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Papageorgiou General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Efstathios Mitsopoulos
Nephrologist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Efstathios Mitsopoulos, MD
Role: PRINCIPAL_INVESTIGATOR
Papageorgiou General Hospital, Thessaloniki, Greece
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Papageorgiou General Hospital
Thessaloniki, , Greece
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
109/16-01-2007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.